Skip to main content
. Author manuscript; available in PMC: 2016 May 1.
Published in final edited form as: Arthritis Rheumatol. 2015 May;67(8):2097–2107. doi: 10.1002/art.39178

Figure 3. Effects of recombinant TTR variants on cell viability in human chondrocytes.

Figure 3

(A) Chondrocytes were treated with 3 different concentrations of recombinant V122I or T119M TTR (0.2, 1, and 4 µM) for 24 h and cell metabolic activity was assessed by resazurin assay. Graph shows the results from 6 independent experiments using cells from of a total of 6 different normal donors. Values are the mean and SD as the ratio of TTR treated cells to control cells not treated with TTR. *P < 0.05 versus vehicle control. & = P < 0.05 between T119M and V122I. (B) Graph shows the results of a total of 4 donors for apoptosis detection in human chondrocytes treated with 4 µM of TTRs for 72 h. Values are the mean and SD as the ratio of TTR-treated cells to control cells not treated with TTR. * = P < 0.05 versus vehicle control. (C) Chondrocytes were treated with V122I TTR (4 µM) with or without resveratrol for 24 h and cell metabolic activity was assessed by Resazurin assay. Graph shows the results of a total of 5 donors. Values are the mean and SD as the ratio of TTR treated cells to vehicle control cells.